VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

B16 melanoma DNA vaccine pSin-hTRP-1 encoding TRP-1
Vaccine Information
  • Vaccine Name: B16 melanoma DNA vaccine pSin-hTRP-1 encoding TRP-1
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0004429
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • Tyrp1 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0005011
  • Preparation: The replicase-based plasmids (pSin-mTRP-1, pSin-hTRP-1) are derived from pSin-β-gal (Leitner et al., 2003).
  • Immunization Route: Gene gun
  • Description: This vaccine has been used in research involving melanoma. (Leitner et al., 2003)
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: To test the efficacy of replicase-based TRP-1 plasmids, gene-gun−immunized mice were challenged subcutaneously with B16 melanoma. This vaccine provided strong tumor protection, with around 60% of mice still tumor-free 21 days after challenge (Leitner et al., 2003).
References
Leitner et al., 2003: Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature medicine. 2003; 9(1); 33-39. [PubMed: 12496961].